EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Thoracic perivascular adipose tissue-derived PI16 alleviates vascular calcification via CKAP4/PI3K/Akt pathway

Shu Qiu, Weixia Gao, Dongxue Wu, Wenwen Lu, Jiapeng Li, Qihao Guo, Xin Wang, Xiaoman Ji, Yuhang Wang, Yixuan Wang, Xiaoxue Li, Guangjie Tai und 1 weitere

Pharmacological Research · 2026-07 · 229 · 108258

DOI: 10.1016/j.phrs.2026.108258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Research, 2026-07. Verfasst von Shu Qiu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Hauptthemen laut MEDLINE: Vascular Calcification, Adipose Tissue, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Manchester Biomedical Research Centre, China Postdoctoral Science Foundation, Harbin Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medial arterial calcification (MAC) is a major vascular complication of chronic kidney disease (CKD) and a strong predictor of cardiovascular morbidity and mortality, yet pharmacological interventions directly targeting this process remain limited. Thoracic perivascular adipose tissue (tPVAT) is increasingly recognized as a regulator of vascular homeostasis, but its role in medial arterial calcification remains unclear. Here we investigated whether tPVAT confers protection against medial arterial calcification and the underlying mechanisms. Using complementary experimental models of vascular calcification, including adenine-induced CKD and vitamin D3-induced calcification, we found that the thoracic aorta exhibited delayed medial calcification compared with the abdominal aorta. Transplantation of tPVAT attenuated abdominal aortic calcification across multiple models. A factor derived from early-stage tPVAT suppressed vascular smooth muscle cell calcification in vitro. Peptidase inhibitor 16 (PI16), predominantly derived from fibroblasts, was identified as a key anti-calcific factor in tPVAT, and its protective effect was confirmed using recombinant PI16. Mechanistically, PI16 interacted with cytoskeleton-associated protein 4 (CKAP4), a membrane-associated protein on vascular smooth muscle cells, resulting in inhibition of the PI3K/Akt/RUNX2 signaling pathway and suppression of osteogenic differentiation. These findings identify PI16 as a tPVAT-derived inhibitor of vascular calcification and reveal a PI16-CKAP4 signaling pathway that may represent a potential therapeutic target in CKD-associated vascular calcification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular CalcificationAdipose TissueProto-Oncogene Proteins c-aktAnimalsSignal TransductionMaleMuscle, Smooth, VascularAorta, ThoracicPhosphatidylinositol 3-KinasesRenal Insufficiency, ChronicMyocytes, Smooth MuscleMice, Inbred C57BLCells, CulturedRats, Sprague-DawleyAdenine

Stichwörter der Autor:innen

CKAP4Chronic kidney diseaseMedial arterial calcificationPI16Perivascular adipose tissueVascular smooth muscle cells

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesAdenine

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
  • Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
  • Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
  • Department of Cardiology, The Second Hospital of Nanjing Affiliated to Nanjing University of Chinese Medicine, Nanjing 210003, China. Electronic address: lxx84112@163.com.
  • Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Electronic address: taiguangjie@cpu.edu.cn.
  • Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Electronic address: mingxu@cpu.edu.cn.

Förderung

  • Manchester Biomedical Research Centre
  • China Postdoctoral Science Foundation
  • Harbin Medical University
  • National Natural Science Foundation of China

Zitieren

APA

Qiu, S., Gao, W., Wu, D., Lu, W., Li, J., Guo, Q., Wang, X., Ji, X., Wang, Y., Wang, Y., Li, X., Tai, G., & Xu, M. (2026). Thoracic perivascular adipose tissue-derived PI16 alleviates vascular calcification via CKAP4/PI3K/Akt pathway. Pharmacological Research, 229, 108258. https://doi.org/10.1016/j.phrs.2026.108258

Vancouver

Qiu S, Gao W, Wu D, Lu W, Li J, Guo Q, et al. Thoracic perivascular adipose tissue-derived PI16 alleviates vascular calcification via CKAP4/PI3K/Akt pathway. Pharmacological Research. 2026;229:108258. doi:10.1016/j.phrs.2026.108258

BibTeX
@article{Qiu2026,
  author = {Qiu, Shu and Gao, Weixia and Wu, Dongxue and Lu, Wenwen and Li, Jiapeng and Guo, Qihao and Wang, Xin and Ji, Xiaoman and Wang, Yuhang and Wang, Yixuan and Li, Xiaoxue and Tai, Guangjie and Xu, Ming},
  title = {Thoracic perivascular adipose tissue-derived PI16 alleviates vascular calcification via CKAP4/PI3K/Akt pathway},
  journal = {Pharmacological Research},
  year = {2026},
  volume = {229},
  pages = {108258},
  doi = {10.1016/j.phrs.2026.108258}
}
Kostenlos starten →